Aims We examined prevalence and progression of retinopathy in dependence on diabetes duration in order to estimate the probability of progression. Patients/Methods In a retrospective cohort-analysis from an academic outpatient department of endocrinology and metabolic diseases we analyzed 17461 consultations of 4513 patients with DM2 from 1987 to 2014. 50.3 % of the patients (n = 2272) had at least one documented result of funduscopy. Results 25.8 % of the patients had retinopathy (20.2 % nonproliferative, 4.7 % proliferative, 0.7 % were not classified, 0.1 % blindness). The prevalence of retinopathy in dependence on diabetes duration was 1.1 % at diagnosis, 6.6 % after 0 < 5 years, 12 % after 5 < 10 years, 24 % after 10 < 15 years, 39.9 % after 15 < 20 years, 52.7 % after 20 < 25 years, 58.7 % after 25 < 30 years and 63 % after ≥ 30 years. In a subset of 586 (25.7 %) patients with retinal photography of 3 consecutive years 7.0 % showed deterioration after one and 12.2 % after two years; 2.6 % improved after one and 2.8 % after two years. 201 (34.3 %) of this group had < 10 years diabetes and lower deterioration (4.5 % worsened after one and 9.5 % after two years). Their retinopathy mainly transformed from no retinopathy to nonproliferative. Four patients (2.0 %) developed proliferative retinopathy. Conclusions/Interpretations Within the first 10 years of diabetes duration, the prevalence of retinopathy is low and the progression infrequent. Most patients have a non-proliferative form which can be reversible and rarely requires interventions. Patients with DM2 without retinopathy and good glycaemic control do not run into additional risk from expanding funduscopy intervals to biennial.
Introduction
Diabetic retinopathy (DR) is a microangiopathic transformation of the retina and a sequel of diabetes mellitus (DM). Left undiagnosed and untreated before the manifestation of symptoms, it may result in inexorable visual loss or even blindness. Despite of advanced treatment options, DR is still one of the most frequent causes of blindness within the working population of industrial countries [1] [2] [3] . Therefore, it is recommended by the DDG (German Diabetes Association 2015) and the NVL (National guideline for diabetic eye disease 2015) to screen patients with type 2 diabetes (DM2) regularly for DR because early detection and medical treatment are essential to preserve eyesight.
Avoiding unnecessary screening procedures is mandatory considering the steadily increasing prevalence of DM2 [4] in order to prevent over-diagnosis and control health care costs [5] . In consequence, screening should provide safety for the patient as well as maximal efficiency.
In order to determine an appropriate screening interval it is important to estimate the individual risk of DR development and progression. This risk may be dependent on diabetes duration, which often is not taken into account either because it is not established or only indicated as a mean value [6] . Therefore, the aim of this study was to use the data of an academic outpatient Department for Endocrinology and Metabolic diseases to determine the prevalence of DR in dependence on the duration of DM2 and to assess the likelihood of rapid progression to irreversible extend, especially within the first 10 years after the diagnosis of DM.
Methods
Retrospective data were provided by the outpatient department of Endocrinology and Metabolic diseases, University Hospital Jena. All diagnostic findings from 1987 to 2014 were included. Consultations were primarily documented handwritten and subsequently with the electronic patient file EMIL (http://cleverdoku.de/index. php/emilhome/emil; accessed 25.01.16). For this particular study, all patients with a diagnosis of DM2 were preselected.
Study population
Within 27 years 17461 consultations of 4513 patients with DM2 were registered. Of these patients 50.3 % (n = 2272) had at least one documented result of funduscopy and consequently were included in the analysis. Patients had their first consultation at the health care center in different years and with varying diabetes duration. At the first visit, the type of diabetes and the duration of the disease were assessed. At baseline and further on yearly, the status of DR, screening for diabetic neuropathy of the feet, serum creatinine measurement and albuminuria were documented, whereas HbA 1c , plasma glucose, blood pressure and body weight were documented at each consultation, usually three or four times a year.
Measurements
HbA 1c was DCCT-adjusted (Muller et al. 1999 ). Information about the onset of diabetes was either obtained by medical evidence or by the patients case history.
Retinopathy DR-grading relied on medical reports from the treating ophthalmologists.
The internationally accepted RD-classification of the "Early Treatment Diabetic Retinopathy Study Group" (ETDRS) [7] was simplified by the "Global Diabetic Retinopathy Project Group" in 2003 [8] . Both are the basis of national and European guidelines, concerning the medical supervision of patients with diabetes [9] . This study classified into: no retinopathy (DR 0 no micro-aneurysm), non-proliferative retinopathy (NPDR, DR 1 -DR 3 retina shows one or more micro-aneurysms, retinal hemorrhages, venous beading, retinal microvascular abnormalities), proliferative retinopathy (PDR, DR 4 retina has manifestations of neovascularization or preretinal hemorrhages of the vitreous body) and blindness. Furthermore, diabetic maculopathy may occur as a manifestation of diabetic microangiopathy of the eyes and may impair visual acuity. Some patients had macular edema (ME) as well as DR but the findings and manifestation of ME were seldom satisfyingly documented if not sight-threatening, especially in the older reports, where diagnosis and classification of ME was not feasible for ambulant ophthalmologists. Therefore we concentrated on DR, and the few patients with explicit documentation of clinically significant macula edema (CSME) were excluded (▶Table 1, 2).
Grading was performed on both eyes and only the grading of the worse eye was selected for analysis. If patients had more than one visit within one time periode, only the last visit was included. Blindness was defined as blindness in at least one eye. Regression of DR was defined only as transition from NPDR to no DR.
Medical evidence of all patients who had DR within less than 10 years of diabetes duration, or whose DR diagnosis fluctuated, who had a non-classified form of DR, CSME, or who were blind because of DR, has been checked and verified manually to prevent transcription errors on the basis of the original medical reports. If photodocumentation of these cases was accessible, an ophthalmologist reevaluated the fundus. If classification could not be ascertained, DR-severity was determined on the basis of the diagnostic findings of the following medical evidence.
Statistical analysis
Patient's characteristics were described by means and standard deviation for continuous variables, absolute and relative frequency for categorical variables. Intergroup differences were examined subject to the type of scale using either Mann-Whitney-U-Test or T-test. Binary logistic or linear regression models were fitted. Furthermore, the percentage of DR-free patients over time was depicted by using Kaplan-Meier-curves for the whole sample adjust-ed by HbA 1c , blood pressure and gender. A p-value < 0.05 was considered to be statistically significant. Statistical analysis was performed with IBM SPSS Statistics 22 (IBM Corp., Armonk. NY).
Results
The 2272 patients with DM2 with at least one documented result of funduscopy were divided into 7 groups according to their diabetes duration: G1: 0 < 5 years diabetes duration, G2: 5 < 10 years, G3: 10 < 15 years, G4: 15 < 20 years, G5: 20 < 25 years, G6: 25 < 30 years, G7: > 30 years (▶Table 3). Within these groups DR-severity was determined. The different degrees of DR were analyzed in dependence to HbA 1c , BMI, age, blood pressure and serum creatinine levels as shown in the Supplementary material (Table S1-S7). ▶ Table 3 overviews these groups and indicates that as diabetes duration proceeds, the number of patients without DR decreases while the number of patients with NPDR increases slowly. The numbers of patients with PDR increases even slower as well and there are only four cases of blindness due to DR during the observational period. Furthermore, the Kaplan-Meier curve (▶ Fig. 1 ) demonstrates that especially within the period of the first 10 years of diabetes, 88 % of the patients are without DR. After 15 years the percentage of patients with DR increases more rapidly and after 20 years, more than 50 % are affected.
Funduscopy reports of three consecutive years were available of 586 (25.7 %) patients (diabetes duration 14.3 ± 8.6 years, HbA 1c 7.0 % ± 1.0 (53.0 mmol/mol ± 10.9), age 65.2 ± 9.8 years). Those who had no report of ME or unclassified DR (n = 12) were separately assessed for their progression rate of DR (▶Table 4).
A constant but slow gradual deterioration during this follow-up was apparent. patients with less than 10 years of diabetes was analyzed separately. These patients had an average diabetes duration of 5.3 ± 2.7 years, HbA 1c of 6.9 % ± 1.1 (51.9 mmol/mol ± 12.0) and age of 61.7 ± 11.5 years. ▶ Table 5 shows the severity of DR during the two years follow-up.
From DR-rate at baseline to the first year only 4.5 % (n = 9) had worse diagnostic findings and between baseline and the second year 9.5 % (n = 19) deteriorated. This shows a considerably lower tendency of deterioration within the first 10 years of diabetes du-572 ▶Table ration. Noticeably, of the 19 patients whose diagnostic findings were worse only 4 developed a PDR and none became blind due to DR. Thus, especially within the first 10 years of diabetic duration, progression of DR is low and mainly from no DR to NPDR.
Discussion
In this study we analyzed the correlation between prevalence and progression of DR in dependence of diabetes duration. Prevalence of DR was dependent on diabetes duration and was low especially within the first 10 years. Occasionally improvement from NPDR to no DR could be observed as well. This is probably not a genuine disease regression with normal retinal perfusion because local exudates and hemorrhages can be resorbed. However, the fact that no further microaneurysms emerge might correlate with an improvement of the disease [10] . These findings are in line with data from Zavrelova et al. where 165 people (4.9 %) experienced a slow regression from NPDR to no DR. [11] .
Information about DR-prevalence is diverse and dependent on the selection of patients, their ethnicity and risk factors, diagnostic criteria, study design and time space. Moreover within a nondiabetic population, retinal modifications that would have been wrongly interpreted as mild stages of DR are apparent in 10 % [6] .
The [13] . In 2010, based on health insurance data, a cohort of 2.7 million people from Germany with DM2 were analysed for diabetes-related complications and showed a DR prevalence of 7.1 % [14] . 503885 patients with DM2 participating in the disease management program (DMP) in the area of Nordrhein in 2013 presented a DR prevalence of 9.3 % [15] . 
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Total occurrences These data included only patients from a primary medical-care setting. Most patients with good glycaemic control without diabetes related complications contact their general practitioner and local ophthalmologist regularly and remain within the primary medical care. This explains the lower prevalence compared with our cohort of secondary or tertiary care. With 20 % retinopathy, Hammes et al. found a similar prevalence of retinopathy in a survey from specialized hospital departments [16] .
Another aspect is the regression of DR prevalence, represented by data from 1998 (Wolfsburg study) until 2013 (DMP Nordrhein) supposedly due to better treatment and control. Kloos et al. showed an improvement of HbA 1c and blood pressure in a ten years period in Germany [17] . For the United States Klein and Klein could demonstrate that after the Diabetes Control and Complications Trial (DCCT) [18] and the UK Prospective Diabetes Study (UKPDS) [19] as a consequence of improved glycaemic control, a reduction of DR prevalence and progression occurred [20] . Our data ranges from 1987 to 2014 and therefore comprises a time period when DR prevalence was higher.
Screening for diabetes prevalence in the general population the Gutenberg Health Study was a large population-based study that achieved funduscopy of 1045 people with DM (79.6 % DM2) [6] . 27.7 % of the participants did not know about their diabetes or were not taking anti-diabetic medication. Within this group a DR prevalence of 21.7 % was found which could be subdivided in 17.2 % with mild or moderate NPDR, 2.4 % with severe NPDR and 2.0 % with PDR, showing, that in a population with a considerable proportion of patients with unidentified or untreated DM, DR prevalence is much higher. But even in the control examinations approxiamately 10 % had retinal variations, that could have been diagnosed as mild stages of DR.
For patients with diabetes mellitus the possibility of attaining a sight threatening form of DR remains an important consideration. Screening programs set up to detect DR before fast progression and initiate laser coagulation treatment prior to vision loss have been a major advance in treating patients with diabetes [21] . This is predominantly important as DR is often asymptomatic until an irreversible form of PDR with vitreous hemorrhaging is reached.
The most important fact is the extent of disease progression that would be acceptable or rather what level of progression would remain without consequences. As long as DR remains mild or moderate, laser treatment is unnecessary and worse vision due to DR is unlikely.
The question whether the screening interval could safely be expanded has recently been discussed by other publications: England proposed designing a model to ameliorate screening intervals in low-risk patients [22] . Iceland developed an algorithm to determine screening intervals aiming for economizing resources [23] . Sweden recommends a larger screening interval as well [24] . Further data from England [25, 26] , Scotland [10] , Turin [27] and Wales [28] suggest considering biennial screening for low risk patients.
Zavrelova et al. published a study with a large cohort of patients with DM2 (n = 3343) included in the Diabetes Care System West-Friesland, the Netherlands and screened annually for six years [11] . This study helped to identify patterns of DR progression, showing that especially in a small group of people with higher HbA 1c levels, fast progression from NPDR to PDR may occur. Therefore a close surveillance of patients with NPDR and poor glycaemic control is advisable. On the other hand Zavrelova identified a large cluster of 2971 patients (88.9 %) without DR. These findings are consistent with our results and underline the assumption, that in patients with lower risk factors the DR progression is slow and could be surveilled with larger screening intervals.
A retrospective four year analysis of the DR Screening Service for Wales showed that although in a large cohort of 49763 patients with DM2, the cumulative incidence of DR was considerable with 26.0 %, the rate of referable DR was low with 1.2 % over four years [28] . The authors conclude that annually screening intervals for people with less than 10 years diabetes duration without insulin treatment could be extended. This is already practiced by the Icelandic screening service [29] .
Porta et al. analyzed the cumulative incidence of referable DR in the six years following a negative screening in a cohort of 4320 patients with DM1 and DM2 and found 10.51 % progressing to referable DR [27] . A subgroup with less than 10 years diabetes duration and without insulin treatment was progressing even slower. He concluded that biennial screening in patients without DR is safe and suggested longer screening intervals. A cohort study in Liverpool (UK) even recommends screening every 3-5 years in DM2 patients without DR [25] and a model of cost-effectiveness in the US suggested individual screening-models with 2-3 year-intervals for patients with DM2 without DR, thus sparing resources for more frequent screening of people with previous findings [30] .
The primary strength of our study is the large number of patients included (n = 2279). Most of them contacted the out-patient department regularly and therefore successive reports and close surveillance of risk factors could be achieved. Our results reflect a realistic setting comprising a long time period.
A limitation is the heterogeneous nature of the documentation. We rely on medical reports from different ophthalmologists of routine care and in most cases had no information about the achievement of the report, whether funduscopy or fundus photography was performed, as current guidelines recommend. This is explained by the large time period of our analysis and the previous limitation of diagnostic contingencies. However most patients regularly contact the same ophthalmologist and therefore a continuous surveillance with the same methods of examination can be expected.
This being a retrospective cohort analysis, there is no possibility in actively checking the fundus again. Also there are slight characteristical differences between the two groups with or without medical reports of their fundus. These are except for diabetes duration not clinically relevant and might be explained by more regular visits of those with documented medical reports and hence better monitoring and therapy of risk factors. They do not suggest a positive selection. The study cohort comprised a population of mainly Caucasian people who had DM2, a mean age of 65.4 years and mean HbA 1c of 7.3 %. Therefore a difference in the prevalence and progression of DR is possible in a population of non-Caucasians, or younger people, or people with inferior glycaemic control. On top of that, the disease duration of the participants differed widely and many patients were included when affected by DM2 for several years.
Our data is congruent to the growing body of evidence that screening intervals could be widened. Particularly within the first 10 years of diabetes duration, the occurrence of DR is comparatively low which supports the new DDG guidelines proposal to allow biennial screening. Nevertheless a necessary precondition is the education of the patients to guarantee the adherence to regular screening keeping in mind that funduscopy is the only available method to detect DR. Furthermore it is necessary to control risk factors like HbA 1c and blood pressure to cut down the risk of increased progressing rates [31] [32] [33] . Adherence to the prescripted intervals for screening is the major precondition on which an individualized screening with biennial intervals for low risk patients could be conducted.
